Ribavirin potentiates the efficacy and toxicity of 2′,3′-dideoxyinosine in the murine acquired immunodeficiency syndrome model

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 1009-1017

  Harvie, Pierrot ^b   Omar, Rabeea F ^b   Dusserre, Nathalie ^b   Lansac, Nicolas ^b   Désormeaux, André ^b   Gourde, Pierrette ^b   Simard, Marie ^b   Tremblay, Michel ^b   Beauchamp, Denis ^b   Bergeron, Michel G ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DIDANOSINE; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TOXICITY TESTING;

ANIMALS; ANTIVIRAL AGENTS; CD4-CD8 RATIO; DIDANOSINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOGLOBULIN M; LYMPHATIC DISEASES; LYMPHOID TISSUE; MICE; MICE, INBRED C57BL; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; RIBAVIRIN; SPLENOMEGALY;

EID: 0030426835     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. AHLUWALIA, G., COONEY, D. A., HARTMAN, N. R., MITSUYA, H., YARCHOAN, R., FRIDLAND, A., BRODER, S. AND JOHNS, D. G.: Anomalous accumulation and decay of 2′,3′-dideoxyadenosine-5′-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2′,3′-dideoxyinosine. Drug Metab. Dispos. 21: 369-376, 1993.
2. ALLEN, L. B., QUENELLE, D. C., WESTBROOK, L., TAYLOR, B. A., PRICHARD, M. N., BKAZIER, A. D., HOLLINGSHEAD, M. G. AND SHANNON, W. M.: In vitro and in vivo enhancement of ddI activity against Rauscher murine leukemia virus by ribavirin. Antiviral Res. 27: 317-323, 1995.
3. BAHA, M., PAUWELS, R., BALZARINI, J., HERDEWIJN, P., DE CLERCQ, E. AND DESMYTER, J.: Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31: 1613-1617, 1987.
4. BALZARINI, J., LEE, C.-K., HERDEWIJN, P. AND DE CLERCQ, E.: Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J. Biol. Chem. 266: 21509-21514, 1991.
5. BALZARINI, J., NAESENS, L., ROBINS, M. J. AND DE CLERCQ, E.: Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J. Acquir. Immune Defic. Syndr. 3: 1140-1147, 1990.
6. BASHAM, T., HOLDENER, T. AND MERIGAN, T.: Intermittent, alternating, and concurrent regimens of zidovudine and 2′-3′ dideoxycytidine in the LP-BM5 murine induced immunodeficiency model. J. Infect. Dis. 163: 869-872, 1991.
7. BASHAM, T., RIOS, D. C., HOLDENER, T. AND MERIGAN, T. C.: Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J. Infect. Dis. 161: 1006-1009, 1990.
8. BERGERON, M. G., TSOUKAS, C. M., ROBERTS, R., GENT, M., AOKI, F., CONLY, J., FALUTZ, J., FANNING, M., FONG, I. W., GARBER, G., GILMORE, N., LANDIS, S., MACFADDEN, D. K., MACKIE, I., MANSELL, P., MARCOUX, A., MONTANER, J. S. G., RACHLIS, A., ROMANOWSKI, B., SCHLECH, W., SINAVE, C., TAYLOR, G., TOMA, E. AND THE CANADIAN STUDY GROUP: Tolerance of ribavirine in early HIV disease. In 7th International Conference on AIDS, June 16-21, 1991, Abstract MB2353, Florence, 1991.
9. BERGERON, M. G., TSOUKAS, C. M., SECURELLA, J., AOKI, F., CONLY, J., FANNING, M., FONG, I. W., GARBER, G., GILMORE, N., LANDIS, S., MACFADDEN, D. K., MACKIE, I., MANSELL, P., MARCOUX, A., MONTANES, J. S. G., RACHLIS, A., ROMANOWSKI, B., SCHLECH, W., SINAVE, G., TAYLOR, G., TOMA, E. AND THE CANADIAN STUDY GROUP: Ribavirin in 462 patients with early HIV disease. In 2nd Annual Canadian National Conference on HIV/AIDS, May 28-29, 1992, Abstract 65, Vancouver, 1992.
10. BERNIER, R., TREMBLAY, M., TSOUKAS, C. AND BERGERON, M. G.: Drug sensitivity of human immunodeficiency virus type I isolates after ribavirin therapy. J. Infect. Dis., in press.
11. BRANDI, G., CASABIANCA, A., SCHIAVANO, G. F., ROSSI, L., FRATERNALE, A., ALBANO, A. AND MAGNANI, M.: Efficacy and toxicity of long-term administration of 2′,3′-dideoxycytidine in the LP-BM5 murine-induced immunodeficiency model. Antiviral Chem. Chemother. 6: 153-161, 1995.
12. CANONICO, P. G., KASTELLO, M. D., COSGRIFF, T. M., DONOVAN, J. C., ROSS, P. E., SPEARS, C. T. AND STEPHEN, E. L.: Hematological and bone marrow effects of ribavirin in Rhesus monkeys. Toxicol. Appl. Pharmacol. 74: 163-172, 1984a.
13. CANONICO, P. G., KASTELLO, M. D., SPEARS, C. T., BROWN, J. R., JACKSON, E. A. AND JENKINS, E.: Effects of ribavirin on red blood cells. Toxicol. Appl. Pharmacol. 74: 155-162, 1984b.
14. CHATTOPADHYAY, S. K., MORSE III, H. C., MAKINO, M., RUSCETTI, S. K. AND HARTLEY, J. W.: Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc. Natl. Acad. Sci. U.S.A. 86: 3862-3866, 1989.
15. DÉSORMEAUX, A., HARVIE, P., PERRON, S., MAKABI-PANZU, B., BEAUCHAMP, D., THEMBLAY, M., POULIN, L. AND BERGERON, M. G.: Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 8: 1545-1553, 1994.
16. EMBRETSON, J., ZUPANCIC, J., RIBAS, J. L., BURKE, A., RACZ, P., TENNER-RACZ, K. AND HAASE, A.: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362: 359-362, 1993.
17. ERIKSSON, B. AND SCHINAZI, R. F.: Combination of 3′-azido-3′deoxythymidine (Zidovudine) and phosphonoformate (Foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 33: 663-668, 1989.
18. FAULDS, D. AND BRODGEN, R. N.: Didanosine. A review of its antiviral activity, pharmacokinetics properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44: 94-116, 1992.
19. FERNANDEZ-LARSSON, R. AND PATTERSON, J. L.: Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Mol. Pharmacol. 38: 766-770, 1990.
20. FISCHL, M. A., STANLEY, K., COLLIER, A. C., ARDUINO, J. M., STEIN, D. S., FEINBERG, J. E., ALLAN, J. D., GOLDSMITH, J. C. AND POWDELY, W. G.: Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122: 24-32, 1995.
21. FOX, C. H., HOOVER, S., CURRALL, V. R., BAHRE, H. J. AND COTTLERFOX, M.: HIV in infected lymph nodes. Nature 370: 256, 1994.
22. GAZZINELLI, R. T., GIESE, N. A. AND MORSE III, H. C.: In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J. Exp. Med. 180: 2199-2208, 1994.
23. GAZZINELLI, R. T., MAKINO, M., CHATTOPADHYAY, S. K., SNAPPER, C. M., SHER, A., HÜGIN, A. W. AND MORSE III, H. C.: CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J. Immunol. 148: 182-188, 1992.
24. GILBERT, B. E. AND KNIGHT, V.: Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30: 201-205, 1986.
25. GILSON, R. J. C., SEMPLE, M., GILL, S. K., LOVEDAY, C., TEDDER, R. S. AND WELLER, I. V. D.: Lack of suppression by ribavirin of HIV viraemia. Lancet 339: 1605-1606, 1992.
26. GOULDEN, M. G., CAMMACK, N., HOPEWELL, P. L., PENN, C. R. AND CAMERON, J. M.: Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 10: 101-102, 1996.
27. HARTLEY, J. W., FREDERICKSON, T. N., YETTER, R. A., MAKINO, M. AND MORSE III, H. C.: Retrovirus-induced murine acquired immunodeficiency syndrome: Natural history of infection and differing susceptibility of inbred mouse strains. J. Virol. 63: 1223-1231, 1989.
28. HARVIE, P., DÉSORMEAUX, A., BERGERON, M.-C., TREMBLAY, M., BEAUCHAMP, D., POULIN, L. AND BERGERON, M. G.: Comparative pharmacokinetics, distribution in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′-3′ dideoxyinosine. Antimicrob. Agents Chemother. 40: 225-229, 1996a.
29. HARVIE, P., DÉSORMEAUX, A., GAGNÉ, N., TREMBLAY, M., POULIN, L., BEAUCHAMP, D. AND BERGERON, M. G.: Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 9: 701-707, 1995.
30. HARVIE, P., OMAR, R. F., DUSSERRE, N., DÉSORMEAUX, A., GOURDE, P., TREMBLAY, M., BEAUCHAMP, D. AND BERGERON, M. G.: Antiviral efficacy and toxicity of ribavirin in MAIDS model. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 12: 451-461, 1996b.
31. HEATH, S. L., TEW, J. G., TEW, J. G., SZAKAI, A. K. AND BURTON, G. F.: Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377: 740-744, 1995.
32. HO, D. D., NEUMANN, A. U., PERELSON, A. S., CHEN, W., LEONARD, J. M. AND MARKOWITZ, M.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126, 1995.
33. HOGGARD, P. G., VEAL, G. J., WILD, M. J., BARRY, M. G. AND BACK, D. J.: Drug interactions with zidovudine phosphorylation in vitro. Antimicrob. Agents Chemother. 39: 1376-1378, 1995.
34. HUGIN, A. W., VACCHIO, M. S. AND MORSE III, H. C.: A virus-encoded "superantigen" in a retrovirus-induced immunodeficiency syndrome of mice. Science 252: 424-427, 1991.
35. HUSSON, R. N., MUELLER, B. U., FARLEY, M., WOODS, L., KOVACS, A., GOLDSMITH, J. C., ONO, J., LEWIS, L. L., BALIS, F. M., BROUWERS, P., AVRAMIS, V. I., CHURCH, J. A., BUTLER, K. M., RASHEED, S., JAROSINSKI, P., VENZON, D. AND PIZZO, P. A.: Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection. Pediatrics 93: 316-322, 1994.
36. JACOBSON, M. A., VAN DER HORST, C., CAUSEY, D. M., DEHLINGER, M., HAFNER, R. AND MILLS, J.: In vivo anti-retroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG protocol 053). J. Infect. Dis. 163: 1219-1222, 1991.
37. KIM, W. K., TANG, Y., KENNY, J. J., LONGO, D. L. AND MORSE III, H. C.: In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages. J. Virol. 68: 6767-6769, 1994.
38. KLINMAN, D. M. AND MORSE III, H. C.: Characteristics of B cell proliferation and activation in murine AIDS. J. Immunol. 142: 1144-1149, 1989.
39. KORT, J. J. AND EISEMAN, J. L.: Interferon-gamma: A potent antiviral agent targeting macrophages infected with LP-BM5 murine leukemia virus, the causative agent of 'AIDS' in mice. Can. J. Infect. Dis. 3: 115B-122B, 1992.
40. LARDER, B. A., KEMP, S. D. AND HARRIGAN, P. R.: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699, 1995.
41. MASUDA, A., BURTON, G. F., SZAKAL, A. K. AND TEW, J. G.: Loss of follicular dendritic cells in murine-acquired immunodeficiency syndrome. Lab. Invest. 73: 511-520, 1995.
42. MONTANER, J. S. G. AND SCHECHTER, M. T.: A year of transformation in HIV/AIDS. Lancet 346: 12, 1995.
43. MORSE III, H. C., CHATTOPADHYAY, S. K., MAKINO, M., FREDRICKSON, T. N., HÜGIN, A. W. AND HARTLEY, J. W.: Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6: 607-621, 1992.
44. MOSIER, D. E., YETTER, R. A. AND MORSE III, H. C.: Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J. Exp. Med. 161: 766-784, 1985.
45. OHNOTA, H., OKADA, Y., USHIJIMA, H., KITAMURA, T., KOMURO, K. AND MIZUOCHI, T.: 3′-azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicrob. Agents Chemother. 34: 605-609, 1990.
46. OMAR, R. F., GOURDE, P., DÉSORMEAUX, A., TREMBLAY, M., BEAUCHAMP, D. AND BERGERON, M. G.: In vivo toxicity of foscarnet and zidovudine each given alone or in combination. Toxicol. Appl. Pharmacol., 139: 324-332, 1996.
47. PANTALEO, G. AND FAUCI, A. S.: Tracking HIV during disease progression. Curr. Opin. Immunol. 6: 600-604, 1994.
48. PANTALEO, G., GRAZIOSI, C., DEMAREST, J. F., BUTINI, L., MONTRONI, M., FOX, C. H., ORENSTEIN, J. M., KOTLER, D. P. AND FAUCI, A. S.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362: 355-358, 1993.
49. PHILLIPS, N. C. AND TSOUKAS, C.: Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79: 1137-1143, 1992.
50. POLIS, M. A., DESMET, M. D., BRAID, B. F., MELLOW, S., FALLOON, J., DAVEY, R. T., KOVACS, J. A., PALESTINE, A. G., NUSSENBLATT, R. B., MASUR, H. AND LANE, H. C.: Increased survival of a cohort of patient with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am. J. Med. 94: 175-179, 1993.
51. PORTNOI, D., STALL, A. M., SCHWARTZ, D., MERIGAN, T. C., HERZENBERG, L. AND BASHAM, T.: Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS. J. Immunol. 144: 1705-1710, 1990.
52. POWERS, C. N., PEAVY, D. L. AND KNIGHT, V.: Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob. Agents Chemother. 22: 108-114, 1982.
53. RICHMAN, D. D., MENG, T.-C., SPECTOR, S. A., FISCHL, M. A., RESNICK, L. AND LAI, S.: Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 7: 135-138, 1994.
54. ROBERTS, R. B., HOLLINGER, F. B., PARKS, W. P., RASHEED, S., LAURENCE, J., HESELTINE, P. N. R., MAKUCH, R. W., LUBINA, J. A., JOHNSON, K. M. AND THE RIBAVIRIN-LAS COLLABORATIVE GROUP: A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: Virologic observations. AIDS 4: 67-72, 1990.
55. ROWE, W. P., PUGH, W. E. AND HARTLEY, J. W.: Plaque assay techniques for murine leukemia viruses. Virology 42: 1136-1139, 1970.
56. SCHRAGER, L. K. AND FAUCI, A. S.: Trapped but still dangerous. Nature 377: 680-681, 1995.
57. SCHULOF, R. S., PARENTI, D. M., SIMON, G. L., PAXTON, H., MEYEK III, W. A., SCHLESSELMAN, B., COURTLESS, J., LELACHEUR, S. AND SZTEIN, M. B.: Clinical, virologic and immunologic effects of ribavirin and isoprinosine in HIV-infected homosexual men. J. Acquir. Immune Defic. Syndr. 3: 485-492, 1990.
58. SENAY, H., TROTTIER, S., MORISSETTE, M., GAREAU, L., BELLES-ISLES, M., JUTRAS, M. AND BERGERON, M. G.: Ribavirin therapy in patients in early stages of HIV infections. In 7th International Conference on AIDS, June 16-21, 1991, Abstract WB2105, Florence, 1991.
59. SHAFER, R. W., IVERSEN, K. N., WINTERS, M. A., AGUINIGA, E., KATZENSTEIN, D., MERIGAN, T. C. AND THE AIDS CLINICAL TRIALS GROUP 143 VIROLOGY TEAM: Drug resistance and heterogenous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172: 70-78, 1995.
60. SMITH, R. A. AND WADE, M.: Ribavirin: a broad spectrum antiviral agent. In Studies with a broad spectrum antiviral agent, ed. by Stapleton, pp. 99-118, Royal Society of Medicine Services, London, 1986.
61. THACORE, H. R., CUNNINGHAM, R. K., ZHOU, P., NAKEEB, S., TERZIAN, R. AND ZALESKI, M. B.: Acquired immunodeficiency in murine lymphoproliferative disease: Considerations on pathogenesis. Immunobiology 190: 195-211, 1994.
62. TOLTZIS, P., O'CONNELL, K. AND PATTERSON, J. L.: Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob. Agents Chemother. 32: 492-497, 1988.
63. VOGT, M. W., HARTSHORN, K. L., FURMAN, P. A., CHOU, T. C., FYFE, J. A., COLEMAN, L. A., CRUMPACKER, C., SCHOOLEY, R. T. AND HIRSH, M. S.: Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235: 1376-1379, 1987.
64. WEI, X., GHOSH, S. K., TAYLOR, M. E., JOHNSON, V. A., EMINI, E. A., DEUTSCH, P., LIFSON, J. D., BONHOEFFER, S., NOWAK, M. A., HAHN, B. H., SAAG, M. S. AND SHAW, G. M.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122, 1995.
65. YARCHOAN, R., LIETZAU, J. A., NGUYEN, B.-Y., BRAWLEY, O. W., PLUDA, J. M., SAVILLE, M. W., WYVILL, K. M., STEINBERG, S. M., AGBARIA, R., MITSUYA, H. AND BRODER, S.: A randomized pilot study of alternative or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J. Infect. Dis. 169: 9-17, 1994.